Adamas Pharmaceuticals (ADMS) Named Best 2018 Idea at Cowen; 'Meaningfully Undervalued'
Tweet Send to a Friend
Cowen analyst Ken Cacciatore named Adamas Pharmaceuticals (NASDAQ: ADMS) a Best Idea for 2018, calling it 'meaningfully undervalued'. The firm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
